Moomoo AIのまとめ
Virpax Pharmaceuticals reported a net loss of $15.2 million for fiscal year 2023, compared to $21.7 million in 2022. Total operating expenses decreased to $15.7 million from $21.8 million, with research and development expenses declining 52% to $5.1 million. The company ended the year with $9.1 million in cash.The company reached a settlement agreement with Sorrento Therapeutics and Scilex Pharmaceuticals, agreeing to pay $6 million in cash payments ($3.5 million paid in March 2024 and $2.5 million due by July 1, 2024) plus 6% royalties on future sales of Epoladerm, Probudur and Envelta products. The settlement resolves all claims against Virpax related to the litigation.Management continues to advance its pipeline of non-opioid pain management candidates, though noting substantial doubt about its ability to continue as a going concern due to continuing losses and cash position. The company will need to raise additional capital to fund operations and make the remaining $2.5 million litigation payment. Development activities for Probudur in Israel may face potential delays due to regional conflicts.
Virpax Pharmaceuticals reported a net loss of $15.2 million for fiscal year 2023, compared to $21.7 million in 2022. Total operating expenses decreased to $15.7 million from $21.8 million, with research and development expenses declining 52% to $5.1 million. The company ended the year with $9.1 million in cash.The company reached a settlement agreement with Sorrento Therapeutics and Scilex Pharmaceuticals, agreeing to pay $6 million in cash payments ($3.5 million paid in March 2024 and $2.5 million due by July 1, 2024) plus 6% royalties on future sales of Epoladerm, Probudur and Envelta products. The settlement resolves all claims against Virpax related to the litigation.Management continues to advance its pipeline of non-opioid pain management candidates, though noting substantial doubt about its ability to continue as a going concern due to continuing losses and cash position. The company will need to raise additional capital to fund operations and make the remaining $2.5 million litigation payment. Development activities for Probudur in Israel may face potential delays due to regional conflicts.
Virpax Pharmaceuticalsは、2023会計年度において1520万ドルの純損失を報告し、2022年の2170万ドルと比較されます。総営業費用は2180万ドルから1570万ドルに減少し、研究開発費は52%減少して510万ドルとなりました。同社は年末に910万ドルの現金を保有していました。同社はSorrento TherapeuticsとScilex Pharmaceuticalsとの間で和解合意に達し、現金で600万ドルの支払い（350万ドルは2024年3月に支払い、250万ドルは2024年7月1日までに支払い）及びEpoladerm、Probudur、Envelta製品の今後の...すべて展開
Virpax Pharmaceuticalsは、2023会計年度において1520万ドルの純損失を報告し、2022年の2170万ドルと比較されます。総営業費用は2180万ドルから1570万ドルに減少し、研究開発費は52%減少して510万ドルとなりました。同社は年末に910万ドルの現金を保有していました。同社はSorrento TherapeuticsとScilex Pharmaceuticalsとの間で和解合意に達し、現金で600万ドルの支払い（350万ドルは2024年3月に支払い、250万ドルは2024年7月1日までに支払い）及びEpoladerm、Probudur、Envelta製品の今後の販売に対する6%のロイヤリティを支払うことに同意しました。この和解は、Virpaxに対する訴訟に関連するすべての請求を解決します。経営陣は、非オピオイド疼痛管理候補のパイプラインを前進させ続けていますが、継続的な損失と現金状況により、継続企業としての能力に対する大きな疑念があることに注意しています。同社は事業を資金調達し、残りの250万ドルの訴訟支払いを行うために追加の資本を調達する必要があります。イスラエルでのProbudurの開発活動は地域的な紛争により潜在的な遅延に直面する可能性があります。
役に立った
役に立たない
